We are live on ! Find out more
PPH icon

VanEck Pharmaceutical ETF
PPH

54 hedge funds and large institutions have $62.9M invested in VanEck Pharmaceutical ETF in 2021 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 18 increasing their positions, 11 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 4

64% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 11

4% more funds holding

Funds holding: 52 → 54 (+2)

43% less call options, than puts

Call options by funds: $416K | Put options by funds: $731K

51.94% less ownership

Funds ownership: 79.37% → 27.43% (-52%)

67% less capital invested

Capital invested by funds: $188M → $62.9M (-$125M)

Holders
54
Holders Change
+2
Holders Change %
+3.85%
% of All Funds
0.94%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
18
Reduced
11
Closed
4
Calls
$416K
Puts
$731K
Net Calls
-$315K
Net Calls Change
+$40.3M

Top Buyers

Rank Fund Capital Flow
1
Osaic Holdings
Osaic Holdings
Arizona
+$2.27M
2
Morgan Stanley
Morgan Stanley
New York
+$1.77M
3
TRCT
Tower Research Capital (TRC)
New York
+$1.18M
4
22CM
20/20 Capital Management
California
+$1.11M
5
Citadel Advisors
Citadel Advisors
Florida
+$519K

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$92.7M
2
Bank of America
Bank of America
North Carolina
-$25.7M
3
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
-$13.8M
4
BCI
Brinker Capital Investments
Pennsylvania
-$4.83M
5
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$3.69M
Name Holding Trade Value Shares
Change 		Change in
Stake
Qube Research & Technologies (QRT)
26
Qube Research & Technologies (QRT)
United Kingdom
$240K +$234K +3,280 New
RJFSA
27
Raymond James Financial Services Advisors
Florida
$206K +$201K +2,817 New
HI
28
Harbour Investments
Wisconsin
$171K +$499 +7 +0.3%
Bank of Montreal
29
Bank of Montreal
Ontario, Canada
$148K +$15.6K +219 +12%
ASN
30
Advisory Services Network
Georgia
$120K +$117K +1,636 New
MA
31
Montag & Associates
Georgia
$101K – – –
TWM
32
Tradition Wealth Management
Minnesota
$95K – – –
GT
33
Glenmede Trust
Pennsylvania
$73K – – –
TCM
34
Tradewinds Capital Management
Washington
$73K – – –
NSIM
35
North Star Investment Management
Illinois
$71K +$71 +1 +0.1%
PSIWM
36
Paradigm Strategies in Wealth Management
Minnesota
$60K – – –
LWM
37
Liberty Wealth Management
California
$44K +$285 +4 +0.7%
LS
38
Leelyn Smith
Illinois
$33K – – –
Citigroup
39
Citigroup
New York
$32K – – –
FDCDDQ
40
Federation des caisses Desjardins du Quebec
Quebec, Canada
$29.2K – – –
S
41
SignatureFD
Georgia
$26K – – –
EIP
42
Ellis Investment Partners
Pennsylvania
$19K +$71 +1 +0.4%
AF
43
Advisornet Financial
Minnesota
$18K +$2.28K +32 +15%
IA
44
IFP Advisors
Florida
$16K -$71 -1 -0.4%
Fidelity Investments
45
Fidelity Investments
Massachusetts
$15K – – –
JCM
46
Jacobi Capital Management
Pennsylvania
$15K – – –
ADL
47
Asset Dedication LLC
California
$11K – – –
HCM
48
Highlander Capital Management
New Jersey
$10K – – –
SPIA
49
Steward Partners Investment Advisory
New York
$6K – – –
AIM
50
Anchor Investment Management
South Carolina
$4.24K – – –
1
2
3

PPH Hedge Fund Activity: Q2 2021 in Review

54 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q2 2021, worth a combined $62.9M — down 67% from $188M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new PPH positions and 4 closed out — a net gain of 3 holders — while 18 added to existing stakes and 11 trimmed.

The largest buyer was Osaic Holdings, adding an estimated $2.27M. The largest seller was Goldman Sachs, cutting an estimated $92.7M.

  • 54 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q2 2021, up from 52 in Q1 2021.
  • Funds reported $62.9M of VanEck Pharmaceutical ETF stock for Q2 2021, down 67% quarter-over-quarter.
  • 7 funds opened new VanEck Pharmaceutical ETF positions in Q2 2021 and 4 closed out, a net change of +3 holders.
  • The largest VanEck Pharmaceutical ETF buyer in Q2 2021 was Osaic Holdings, an estimated $2.27M added.
  • The largest VanEck Pharmaceutical ETF seller in Q2 2021 was Goldman Sachs, an estimated $92.7M sold.

Based on aggregated 13F filings for Q2 2021.